Medical Developments International (MDI) has signed a distribution and licensing agreement with Purdue Pharma for Penthrox Inhaler, Canada.

The low-dose methoxyflurane Penthrox is an inhaled, non-narcotic analgesic drug / device combination that provides emergency relief of moderate to severe pain in conscious adult patients suffering with trauma and associated pain.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

MDI CEO John Sharman said: “This is an exciting deal for MDI and is a critical step towards providing the Canadian healthcare system with another valuable therapeutic option for the treatment of pain.

“Purdue has market leading expertise in pain management products and will invest in providing the educational resources to healthcare practitioners on the appropriate use, benefits, and safety profile of Penthrox.”

"This is an exciting deal for MDI and is a critical step towards providing the Canadian healthcare system with another valuable therapeutic option for the treatment of pain."

Penthrox is approved for marketing in 15 countries including Australia, the UK, Ireland, France and Belgium.

See Also:

Purdue Pharma president and CEO Dr Craig Landau said: “Subject to regulatory approval by Health Canada, Penthrox will provide Canadian patients and ER Physicians with an important, non-opioid treatment option for medical situations involving acute trauma pain that is moderate to severe in nature.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Penthrox nicely complements, and will provide additional diversification to our existing analgesic product portfolio.”

MDI recently received regulatory approval and the marketing authorisation for the sale of Penthrox in the United Arab Emirates.